Skip to main content

Noncoding RNA MEG3 inhibitor for Heart Failure Treatment

Project description

An RNA-based treatment for heart failure

Heart failure is associated with cardiac fibrosis or scarring, an unavoidable consequence of myocardial insult that affects diastolic and systolic function. Despite its great socioeconomic burden, there are no treatments to restore cardiac fibrosis and cure heart failure. The EU-funded MEGFIB project proposes to develop a new approach for treating selected heart failure patients, based on non-coding RNAs, which are emerging as important players in disease pathogenesis. Using oligonucleotides that target the meg3 long non-coding RNA in human cells and tissues, scientists hope to replicate their results in animal models and establish a new approach in heart failure care.

Host institution

MEDIZINISCHE HOCHSCHULE HANNOVER
Net EU contribution
€ 150 000,00
Address
Carl-neuberg-strasse 1
30625 Hannover
Germany
Activity type
Higher or Secondary Education Establishments
Non-EU contribution
No data

Beneficiaries (1)

MEDIZINISCHE HOCHSCHULE HANNOVER
Germany
Net EU contribution
€ 150 000,00
Address
Carl-neuberg-strasse 1
30625 Hannover
Activity type
Higher or Secondary Education Establishments
Non-EU contribution
No data